Most Popular
-
1
'Super Rich in Korea' will leave viewers appreciating Korea more: producers
-
2
Probe of first lady on Dior bag allegations set to begin
-
3
Top prosecutor pledges 'speedy, strict' probe into first lady's luxury bag allegations
-
4
Korean battery makers heave sigh of relief over 2-year IRA reprieve
-
5
Over 80,000 millionaires, 20 billionaires in Seoul: report
-
6
Indonesia’s KF-21 fighter jet deal cut back -- what’s next?
-
7
[KH Explains] Can tech firms' AI alliances take on Nvidia?
![[KH Explains] Can tech firms' AI alliances take on Nvidia?](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/05/07/20240507050619_0.jpg&u=)
-
8
Police seek arrest warrant for med student who killed girlfriend
-
9
Local filmmakers criticize ‘The Roundup: Punishment’ monopoly of screens
-
10
Young Korean doctors seek plan B: cosmetic dermatology or overseas
![[KH Explains] Can tech firms' AI alliances take on Nvidia?](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/05/07/20240507050619_0.jpg&u=)
[THE INVESTOR] South Korean biopharmaceutical firm Bioleaders has passed the final review for transferring its stocks to the country’s tech-heavy KOSDAQ from KONEX, the bourse operator Korea Exchange said on July 5.
Bioleaders will be listed on KOSDAQ on July 7 with the indicative share price set at 15,000 won (US$12.87).
Established in 1999, the firm has a range of core technologies to develop next-generation immunity treatments. In 2015, Bioleaders logged 1.47 billion won in sales and a net loss of 18.6 trillion won.
By Park Han-na (hnpark@heraldcorp.com)
-
Articles by Korea Herald
![[K-pop’s dilemma] Time, profit pressures work against originality](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/05/08/20240508050705_0.jpg&u=20240508171126)
![[Today’s K-pop] NCT Dream to drop pre-release from 2nd Japan single](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=642&simg=/content/image/2024/05/08/20240508050725_0.jpg&u=)